SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
16 references·2 citing·43 second hop
The Effect of Medicare Part D on Pharmaceutical Prices and Utilization (2008)The Effect of Medicare Part D on Pharmace…What did Medicare do? The initial impact of Medicare on mortality and out of pocket medical spending (2007)What did Medicare do? The ini…The Aggregate Effects of Health Insurance: Evidence from the Introduction of Medicare (2007)The Aggregate Effects of Heal…The effects of prescription drug cost sharing: a review of the evidence. (2005)The effects of prescription d…How Do Hospitals Respond to Price Changes? (2005)How Do Hospitals Respond to P…UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE (2003)UNCERTAINTY AND THE WELFARE E…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending (2003)The Effect of Incentive-Based…Generic Entry and the Pricing of Pharmaceuticals (1997)Generic Entry and the Pricing…Generic Entry and the Pricing of Pharmaceuticals (1997)Generic Entry and the Pricing…Does Public Insurance Crowd out Private Insurance? (1996)Does Public Insurance Crowd o…The Incidence of Adverse Medical Outcomes Under Prospective Payment (1995)The Incidence of Adverse Medi…Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry (1991)Patent Expiration, Entry, and…Health insurance and the demand for medical care: evidence from a randomized experiment. (1987)Health insurance and the dema…Incentives to Form Coalitions with Bertrand Competition (1985)Incentives to Form Coalitions…Market Structure and Behavior (1980)Market Structure and BehaviorSupplier-Induced Demand: Some Empirical Evidence and Implications (1974)Supplier-Induced Demand: Some…Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (2020)Investing in Ex Ante Regulati…Medicare Part D Update — Lessons Learned and Unfinished Business (2009)Medicare Part D Update — Less…Health: United States (1986)Free for All? Lessons from the RAND Health Insurance Experiment (1995)New Evidence on the Money's Worth of Individual Annuities (1999)Does progress towards universal health coverage improve population health? (2012)The Oregon Health Insurance Experiment: Evidence from the First Year* (2012)The Association Between Income and Life Expectancy in the United States, 2001-2014 (2016)The Theory of Monopolistic Competition (1957)MONOPOLISTIC COMPETITION AND OPTIMUM PRODUCT DIVERSITY (1975)Quantity precommitment and Bertrand competition yield Cournot outcomes (1989)Quantifying the Benefits of New Products: The Case of the Minivan (2002)Competition and Strategic Information Acquisition in Credit Markets (2006)Cross-Border Mergers as Instruments of Comparative Advantage (2007)Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information (1976)Limited-Dependent and Qualitative Variables in Econometrics (1983)The Determinants of Mortality (2006)Best care at lower cost: the path to continuously learning health care in America (2014)Social Security, Induced Retirement, and Aggregate Capital Accumulation (1974)The incidence of mandated maternity benefits. (1994)Health Insurance Eligibility, Utilization of Medical Care, and Child Health (1996)Saving Babies: The Efficacy and Cost of Recent Changes in the Medicaid Eligibility of Pregnant Women (1996)Does Income Inequality Lead to Consumption Inequality? Evidence and Theory1 (2006)Cost of innovation in the pharmaceutical industry (1991)Stocks, bonds, bills, and inflation yearbook (1993)Risks in new drug development: Approval success rates for investigational drugs (2001)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Health Care Financing Review (1980)Transfers in Cash and In-Kind: Theory Meets the Data (2008)Do Physicians' Financial Incentives Affect Medical Treatment and Patient Health? (2014)The Quarterly Journal of Economics (2024)A Theory of Yardstick Competition (1985)Medicare upcoding and hospital ownership (2004)Price Discrimination and Bargaining: Empirical Evidence from Medical Devices (2013)How Does Risk Selection Respond to Risk Adjustment? New Evidence from the Medicare Advantage Program (2014)Professional uncertainty and the problem of supplier-induced demand (1982)Physician response to fee changes with multiple payers (1991)Physician Agency (2000)Price and Quantity Competition in a Differentiated Duopoly (1984)The Introduction and Performance of Store Brands (1995)The economic analysis of advertising (2005)The Theory of Incentives: The Principal-Agent Model (2001)Understanding and Mitigating Uncertainty in Online Exchange Relationships: A Principal–Agent Perspective1 (2007)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,312 cited
  • 2003UNCERTAINTY AND THE WELFARE ECONOMICS OF MEDICAL CARE4,128 cited
  • 1987Health insurance and the demand for medical care: evidence from a randomized experiment.2,043 cited
  • 1985Incentives to Form Coalitions with Bertrand Competition787 cited
  • 1996Does Public Insurance Crowd out Private Insurance?772 cited
  • 1974Supplier-Induced Demand: Some Empirical Evidence and Implications598 cited
  • 1980Market Structure and Behavior558 cited
  • 2007The Aggregate Effects of Health Insurance: Evidence from the Introduction of Medicare529 cited
  • 2007What did Medicare do? The initial impact of Medicare on mortality and out of pocket medical spending404 cited
  • 2005How Do Hospitals Respond to Price Changes?400 cited
  • 1991Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry399 cited
  • 1997Generic Entry and the Pricing of Pharmaceuticals388 cited
  • 2003The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending334 cited
  • 2005The effects of prescription drug cost sharing: a review of the evidence.266 cited
  • 1997Generic Entry and the Pricing of Pharmaceuticals

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

260 cited
  • 1995The Incidence of Adverse Medical Outcomes Under Prospective Payment217 cited
  • Cited by

    • 2009Medicare Part D Update — Lessons Learned and Unfinished Business54 cited
    • 2020Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination47 cited